Monoclonal antibodies (MoAb)augment the host anti-tumorresponse by selectively target-ing the malignant cells. MoAb can mediate anti-tumor effects through three major mechanisms including intrinsic cytotoxic activity, antibody-dependent cellular cytotoxicity (ADCC), and activation of comple-ment-dependent cytolysis. Alemtuzum-ab is a humanized IgG1MoAb that tar-gets the glycosylated peptide cell sur-face antigen CD52 that is abundantly expressed (approximately 500,000 molecules/cell) on normal and malig-nant B- and T-cells, but not on hemat-opoietic stem cells. It was approved b
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.